Orexo Ab Stock Performance
| ORXOF Stock | USD 1.08 0.00 0.00% |
The company holds a Beta of 0.35, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Orexo AB's returns are expected to increase less than the market. However, during the bear market, the loss of holding Orexo AB is expected to be smaller as well. At this point, Orexo AB has a negative expected return of -0.44%. Please make sure to check Orexo AB's coefficient of variation, maximum drawdown, as well as the relationship between the Maximum Drawdown and day typical price , to decide if Orexo AB performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Orexo AB has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fragile performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long-run up-swing for the company stockholders. ...more
| Begin Period Cash Flow | 505.3 M | |
| Total Cashflows From Investing Activities | -52.9 M | |
| Free Cash Flow | -281.8 M |
Orexo |
Orexo AB Relative Risk vs. Return Landscape
If you would invest 150.00 in Orexo AB on September 3, 2024 and sell it today you would lose (42.00) from holding Orexo AB or give up 28.0% of portfolio value over 90 days. Orexo AB is currently producing negative expected returns and takes up 3.5% volatility of returns over 90 trading days. Put another way, 31% of traded otc stocks are less volatile than Orexo, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Orexo AB Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Orexo AB's investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Orexo AB, and traders can use it to determine the average amount a Orexo AB's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.125
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ORXOF |
Estimated Market Risk
| 3.5 actual daily | 31 69% of assets are more volatile |
Expected Return
| -0.44 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.12 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Orexo AB is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Orexo AB by adding Orexo AB to a well-diversified portfolio.
Orexo AB Fundamentals Growth
Orexo OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Orexo AB, and Orexo AB fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Orexo OTC Stock performance.
| Return On Equity | -0.65 | |||
| Return On Asset | -0.0965 | |||
| Profit Margin | (0.28) % | |||
| Current Valuation | 76.98 M | |||
| Shares Outstanding | 34.35 M | |||
| Price To Earning | 58.66 X | |||
| Price To Book | 2.02 X | |||
| Price To Sales | 0.99 X | |||
| Revenue | 565 M | |||
| EBITDA | (141.3 M) | |||
| Cash And Equivalents | 45.61 M | |||
| Cash Per Share | 1.32 X | |||
| Total Debt | 492.3 M | |||
| Debt To Equity | 1.76 % | |||
| Book Value Per Share | 1.07 X | |||
| Cash Flow From Operations | (229 M) | |||
| Total Asset | 1.27 B | |||
| Current Asset | 907 M | |||
| Current Liabilities | 303 M | |||
About Orexo AB Performance
By analyzing Orexo AB's fundamental ratios, stakeholders can gain valuable insights into Orexo AB's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Orexo AB has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Orexo AB has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Orexo AB , a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, Europe, and the United Kingdom. Orexo AB was incorporated in 1994 and is headquartered in Uppsala, Sweden. Orexo Ab is traded on OTC Exchange in the United States.Things to note about Orexo AB performance evaluation
Checking the ongoing alerts about Orexo AB for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Orexo AB help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Orexo AB generated a negative expected return over the last 90 days | |
| Orexo AB has some characteristics of a very speculative penny stock | |
| Orexo AB has high historical volatility and very poor performance | |
| The company reported the revenue of 565 M. Net Loss for the year was (223.5 M) with profit before overhead, payroll, taxes, and interest of 521.7 M. | |
| Orexo AB has accumulated about 45.61 M in cash with (229 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.32, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 17.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Orexo AB's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Orexo AB's stock is overvalued or undervalued compared to its peers.
- Examining Orexo AB's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Orexo AB's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Orexo AB's management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Orexo AB's otc stock. These opinions can provide insight into Orexo AB's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Orexo OTC Stock analysis
When running Orexo AB's price analysis, check to measure Orexo AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Orexo AB is operating at the current time. Most of Orexo AB's value examination focuses on studying past and present price action to predict the probability of Orexo AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Orexo AB's price. Additionally, you may evaluate how the addition of Orexo AB to your portfolios can decrease your overall portfolio volatility.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |